Gyre Therapeutics Holds 2025 Annual Stockholders Meeting

Gyre Therapeutics ( (GYRE) ) just unveiled an announcement.

On June 4, 2025, Gyre Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders, where all director nominees were elected and other proposals were approved. The meeting included the election of Class I directors to serve until the 2028 Annual Meeting, approval of executive compensation on a non-binding basis, and ratification of Grant Thornton Zhitong Certified Public Accountants LLP as the independent auditor for 2025.

The most recent analyst rating on (GYRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.

Spark’s Take on GYRE Stock

According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.

Gyre Therapeutics’ stock score is primarily influenced by mixed financial performance and bearish technical indicators. The recent positive corporate events provide some upside potential, but high valuation metrics and liquidity concerns pose significant risks.

To see Spark’s full report on GYRE stock, click here.

More about Gyre Therapeutics

Gyre Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of therapeutic solutions. The company is primarily engaged in the research and development of innovative treatments, with a market focus on addressing unmet medical needs.

Average Trading Volume: 252,862

Technical Sentiment Signal: Sell

Current Market Cap: $775M

For a thorough assessment of GYRE stock, go to TipRanks’ Stock Analysis page.